PE20001302A1 - Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida - Google Patents
Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazidaInfo
- Publication number
- PE20001302A1 PE20001302A1 PE1999001171A PE00117199A PE20001302A1 PE 20001302 A1 PE20001302 A1 PE 20001302A1 PE 1999001171 A PE1999001171 A PE 1999001171A PE 00117199 A PE00117199 A PE 00117199A PE 20001302 A1 PE20001302 A1 PE 20001302A1
- Authority
- PE
- Peru
- Prior art keywords
- hydrochlorothiazide
- carvedilol
- film suspension
- granulate
- weight
- Prior art date
Links
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 title abstract 4
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004195 carvedilol Drugs 0.000 title abstract 4
- 229960002003 hydrochlorothiazide Drugs 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000000725 suspension Substances 0.000 abstract 4
- 239000008187 granular material Substances 0.000 abstract 3
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 abstract 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 229960001275 dimeticone Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000004922 lacquer Substances 0.000 abstract 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 abstract 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 abstract 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000000454 talc Substances 0.000 abstract 1
- 229910052623 talc Inorganic materials 0.000 abstract 1
- 239000004408 titanium dioxide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA PREPARACION DE UNA COMBINACION FARMACEUTICA DE a)DE 10mg A 50mg DE CARVEDILOL; b)DE 5mg A 30mg DE HIDROCLOROTIAZIDA; c)ADITIVOS TAL COMO AGLUTINANTES, DESINTEGRANTES, DESLIZANTES, AGENTES DE ADSORCION, AGENTES SEPARADORES, SUSTANCIAS DE CARGA; QUE COMPRENDE a)TRATAR UN GRANULADO DE CARVEDILOL Y UN GRANULADO DE HIDROCLOROTIAZIDA HASTA OBTENER UNA MASA PRENSADA SIENDO EL CONTENIDO DE HUMEDAD DE CADA GRANULADO DE 6% A 20%; Y LA DENSIDAD A GRANEL ENTRE 0,1 g/ml A 1,5 g/ml; b)PRODUCIR LA FORMA DE DOSIFICACION SOLIDA A PARTIR DE LA MASA PRENSADA; c)RECUBRIR CON UNA SUSPENSION DE PELICULA DE 30g A 50g DE UNA SUSPENSION DE PELICULA DURANTE 30 A 70 MINUTOS; LUEGO 60g A 90g DE SUSPENSION DE PELICULA POR MINUTO HASTA QUE FINALIZE EL RECUBRIMIENTO CON LA SUSPENSION DE PELICULA; LA QUE PROTEGE DE LA LUZ; QUE CONTIENE 10% A 50% EN PESO DE POLI(ETILACRILATO, METILACRILATO), DE 1% A 10% EN PESO DE CITRATO DE SODIO; DE 1% A 25% DE METILHIDROXIPROPILCELULOSA; 0% A 20% DE MAGROCOL; 5% A 40% DE TALCO; 2% A 25% DE DIOXIDO DE TITANIO; DE 0% A 10% DE LACA DE COLOR; DE 0% A 2% DE POLISORBATO; O% A 1% DE DIMETICONA; LA COMPOSICION SE CARACTERIZA POR LA RELACION EN PESO DE HIDROCLOROTIAZIDA A CARVEDILOL ES DE 1:0,5 A 1:10. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE TRASTORNOS CARDIACOS Y CIRCULATORIOS TAL COMO HIPERTENSION, ANGINA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98122489 | 1998-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20001302A1 true PE20001302A1 (es) | 2000-11-30 |
Family
ID=8233041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999001171A PE20001302A1 (es) | 1998-11-27 | 1999-11-19 | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US6403579B1 (es) |
| EP (1) | EP1131072B1 (es) |
| JP (2) | JP2002531395A (es) |
| KR (1) | KR100421347B1 (es) |
| CN (1) | CN1184971C (es) |
| AR (1) | AR020287A1 (es) |
| AT (1) | ATE238056T1 (es) |
| AU (1) | AU765977B2 (es) |
| BR (1) | BR9915610A (es) |
| CA (1) | CA2352361C (es) |
| CO (1) | CO5011053A1 (es) |
| DE (1) | DE69907252T2 (es) |
| DK (1) | DK1131072T3 (es) |
| ES (1) | ES2195638T3 (es) |
| MY (1) | MY121831A (es) |
| PE (1) | PE20001302A1 (es) |
| PT (1) | PT1131072E (es) |
| TR (3) | TR200200981T2 (es) |
| TW (1) | TWI228414B (es) |
| UY (1) | UY25821A1 (es) |
| WO (1) | WO2000032174A2 (es) |
| ZA (1) | ZA200104280B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20001302A1 (es) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
| JP2004518734A (ja) * | 2000-10-24 | 2004-06-24 | スミスクライン・ビーチャム・コーポレイション | カルベジロールの新規処方 |
| US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| IN191028B (es) * | 2001-05-17 | 2003-09-13 | Sun Pharmaceutical Ind Ltd | |
| US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| JP2006500320A (ja) * | 2002-04-30 | 2006-01-05 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール一クエン酸塩一水和物 |
| EP1534270A4 (en) | 2002-06-27 | 2006-05-17 | Sb Pharmco Inc | CARVEDILOL PHOSPHATE SALTS AND / OR ITS SOLVENTS, CORRESPONDING COMPOSITIONS AND / OR TREATMENT PROCEDURES |
| AU2003251627A1 (en) | 2002-06-27 | 2004-01-19 | Sb Pharmco Puerto Rico Inc. | Carvedilol hydrobromide |
| US7429619B2 (en) | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
| US20040151772A1 (en) | 2002-11-08 | 2004-08-05 | Egalet A/S | Controlled release carvedilol compositions |
| US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
| WO2004094378A1 (en) * | 2003-04-21 | 2004-11-04 | Matrix Laboratories Ltd | Process for the preparation of carvedilol form-ii |
| WO2005030201A1 (en) * | 2003-09-26 | 2005-04-07 | Shuyi Zhang | Sustained release preparation containing hydrochlorothiazide |
| JP2007512372A (ja) | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール塩、対応する組成物、送達および／または治療方法 |
| JP2007512350A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール組成物の治療および送達方法 |
| WO2005051322A2 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts |
| SI1691804T1 (sl) * | 2003-12-02 | 2007-10-31 | Nicox Sa | Nitrooksi derivati karvedilola in drugih beta blokatorjev kot antihipertenzivi |
| EP2281556A1 (en) * | 2005-02-25 | 2011-02-09 | F. Hoffmann-La Roche AG | Tablets with improved drugs substance dispersibility |
| EP2269583B1 (en) | 2006-06-16 | 2014-08-13 | LEK Pharmaceuticals d.d. | Pharmaceutical composition comprising hydrochlorothiazide and telmisartan |
| GB0612540D0 (en) * | 2006-06-23 | 2006-08-02 | Novartis Ag | Galenical formulations of organic compounds |
| WO2008114276A1 (en) * | 2007-03-16 | 2008-09-25 | Lupin Limited | Novel oral controlled release composition of carvedilol |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| CA2751667C (en) | 2009-02-06 | 2016-12-13 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
| CA2792647A1 (en) * | 2010-03-10 | 2011-09-15 | Nogra Pharma Limited | Compositions for colon lavage and methods of making and using same |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2815926A1 (de) | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| FR2643556B1 (fr) * | 1989-02-27 | 1993-03-05 | Sanofi Sa | Composition pharmaceutique a liberation prolongee d'acide valproique |
| GB2257363B (en) * | 1991-01-30 | 1994-09-28 | Wellcome Found | Water dispersible tablets containing acyclovir |
| EP0546593B1 (en) * | 1991-10-30 | 1997-09-03 | Glaxo Group Limited | Multi-layered compositions containing histamine or serotonin antagonists |
| TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| US5760069A (en) * | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
| FR2752162B1 (fr) * | 1996-08-07 | 1998-11-06 | Jouveinal Lab | Comprime de maleate de trimebutine pellicule |
| DE19637082A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Schnellzerfallende Pellets |
| PE20001302A1 (es) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
-
1999
- 1999-11-19 PE PE1999001171A patent/PE20001302A1/es not_active Application Discontinuation
- 1999-11-20 AT AT99957320T patent/ATE238056T1/de active IP Right Maintenance
- 1999-11-20 KR KR10-2001-7006570A patent/KR100421347B1/ko not_active Expired - Lifetime
- 1999-11-20 TR TR2002/00981T patent/TR200200981T2/xx unknown
- 1999-11-20 WO PCT/EP1999/008972 patent/WO2000032174A2/en not_active Ceased
- 1999-11-20 TR TR2001/01470T patent/TR200101470T2/xx unknown
- 1999-11-20 CA CA002352361A patent/CA2352361C/en not_active Expired - Lifetime
- 1999-11-20 EP EP99957320A patent/EP1131072B1/en not_active Expired - Lifetime
- 1999-11-20 DE DE69907252T patent/DE69907252T2/de not_active Expired - Lifetime
- 1999-11-20 DK DK99957320T patent/DK1131072T3/da active
- 1999-11-20 AU AU15065/00A patent/AU765977B2/en not_active Expired
- 1999-11-20 JP JP2000584870A patent/JP2002531395A/ja active Pending
- 1999-11-20 TR TR2002/00982T patent/TR200200982T2/xx unknown
- 1999-11-20 BR BR9915610-5A patent/BR9915610A/pt not_active Application Discontinuation
- 1999-11-20 ES ES99957320T patent/ES2195638T3/es not_active Expired - Lifetime
- 1999-11-20 CN CNB998137561A patent/CN1184971C/zh not_active Expired - Lifetime
- 1999-11-20 PT PT99957320T patent/PT1131072E/pt unknown
- 1999-11-23 US US09/447,872 patent/US6403579B1/en not_active Expired - Lifetime
- 1999-11-24 AR ARP990105974A patent/AR020287A1/es unknown
- 1999-11-25 CO CO99074400A patent/CO5011053A1/es unknown
- 1999-11-25 MY MYPI99005155A patent/MY121831A/en unknown
- 1999-11-26 UY UY25821A patent/UY25821A1/es unknown
-
2000
- 2000-02-23 TW TW089103144A patent/TWI228414B/zh not_active IP Right Cessation
-
2001
- 2001-05-24 ZA ZA200104280A patent/ZA200104280B/xx unknown
- 2001-09-05 US US09/946,205 patent/US20020052367A1/en not_active Abandoned
-
2003
- 2003-10-24 US US10/693,243 patent/US20040087578A1/en not_active Abandoned
-
2006
- 2006-10-19 JP JP2006284476A patent/JP2007077160A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000032174A2 (en) | 2000-06-08 |
| ES2195638T3 (es) | 2003-12-01 |
| WO2000032174A3 (en) | 2000-11-16 |
| TR200101470T2 (tr) | 2001-11-21 |
| JP2007077160A (ja) | 2007-03-29 |
| DE69907252D1 (de) | 2003-05-28 |
| TR200200981T2 (tr) | 2002-06-21 |
| AU1506500A (en) | 2000-06-19 |
| US6403579B1 (en) | 2002-06-11 |
| DK1131072T3 (da) | 2003-08-11 |
| CN1328460A (zh) | 2001-12-26 |
| CO5011053A1 (es) | 2001-02-28 |
| EP1131072A2 (en) | 2001-09-12 |
| AU765977B2 (en) | 2003-10-09 |
| ZA200104280B (en) | 2002-08-26 |
| DE69907252T2 (de) | 2004-01-29 |
| KR20010080578A (ko) | 2001-08-22 |
| EP1131072B1 (en) | 2003-04-23 |
| UY25821A1 (es) | 2001-07-31 |
| TWI228414B (en) | 2005-03-01 |
| ATE238056T1 (de) | 2003-05-15 |
| BR9915610A (pt) | 2001-08-14 |
| KR100421347B1 (ko) | 2004-03-06 |
| US20040087578A1 (en) | 2004-05-06 |
| CN1184971C (zh) | 2005-01-19 |
| TR200200982T2 (tr) | 2002-06-21 |
| AR020287A1 (es) | 2002-05-02 |
| US20020052367A1 (en) | 2002-05-02 |
| MY121831A (en) | 2006-02-28 |
| CA2352361A1 (en) | 2000-06-08 |
| PT1131072E (pt) | 2003-08-29 |
| CA2352361C (en) | 2007-01-02 |
| JP2002531395A (ja) | 2002-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20001302A1 (es) | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida | |
| US20110104144A1 (en) | Methods for treating cutaneous lupus using aminoisoindoline compounds | |
| BG60698B2 (en) | Pharmaceutical ACCEPTABLE SALTS | |
| EA199700110A1 (ru) | Композиция с высоким содержанием ацетаминофена для прямого прессования | |
| AR028504A2 (es) | Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial | |
| EP3849558A1 (en) | Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents | |
| CN118453610A (zh) | 用于治疗癌症的csf1r抑制剂 | |
| RU94040864A (ru) | Конденсированные индольные производные, их получение, фармацевтическая композиция | |
| MX9404762A (es) | Composiciones para inhalacion y proceso para su preparacion. | |
| RU2009115782A (ru) | Фармацевтические композиции, содержащие нилотиниб или его соль | |
| EA200101005A1 (ru) | Высокоэффективные композиции, содержащие дигидроэрготамин | |
| UA39168C2 (uk) | Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі | |
| RU92016415A (ru) | Нейрозащитные производные индолона и родственные производные | |
| WO1993020099A3 (en) | Cck and/or gastrin receptor ligands | |
| KR20090112722A (ko) | 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물 | |
| KR20090122933A (ko) | Ｎｋ1 수용체 길항제 및 나트륨 채널 차단제를 포함하는 제약 조성물 | |
| WO2006070325A3 (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| RU93004860A (ru) | Гетероциклические соединения, способ их получения, использование и фармацевтическая композиция | |
| JP2893307B2 (ja) | ニコランジルの製薬的に安定な製剤 | |
| JP2003529542A (ja) | 癌の治療のためのエトドラクの使用 | |
| ES8505379A1 (es) | Un metodo de fabricar 1, 4-dihidropiridina-3-carboxilatos | |
| CN105246480A (zh) | 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物 | |
| RU2292891C2 (ru) | Фармацевтическая композиция с антигиперлипидемической активностью | |
| DE3373094D1 (en) | Sulfonyl urea derivatives, process for their preparation and pharmaceutical compositions containing them | |
| Pedersen | Role of extracellular calcium in isometric contractions of the SHR aorta. Influence of age and antihypertensive treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |